Ravi K Amaravadi Selected Research

Lys01

11/2019	A Potent Autophagy Inhibitor (Lys05) Enhances the Impact of Ionizing Radiation on Human Lung Cancer Cells H1299.
11/2017	ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma.
1/2017	Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma.
9/2012	Lys05: a new lysosomal autophagy inhibitor.
5/2012	Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ravi K Amaravadi Research Topics

Disease

58	Neoplasms (Cancer) 01/2022 - 02/2007
52	Melanoma (Melanoma, Malignant) 01/2022 - 05/2007
4	Neoplasm Metastasis (Metastasis) 08/2020 - 12/2013
3	COVID-19 05/2021 - 01/2021
3	Carcinogenesis 11/2020 - 01/2015
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 11/2017
3	Inflammation (Inflammations) 03/2019 - 01/2015
3	Colonic Neoplasms (Colon Cancer) 01/2017 - 07/2007
3	Hypoxia (Hypoxemia) 01/2017 - 06/2013
3	Lymphoma (Lymphomas) 11/2015 - 02/2007
2	Weight Loss (Weight Reduction) 01/2022 - 08/2014
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 11/2017
2	Colitis 01/2022 - 01/2021
2	Sarcoma (Soft Tissue Sarcoma) 11/2021 - 01/2017
2	Adenocarcinoma 01/2020 - 11/2016
2	Toxic Optic Neuropathy 03/2019 - 10/2014
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 01/2017
2	Pancreatitis 01/2018 - 04/2002
2	Necrosis 01/2017 - 12/2007
2	Disease Progression 12/2016 - 07/2015
1	Infections 01/2021
1	Pathologic Complete Response 08/2020
1	Ovarian Neoplasms (Ovarian Cancer) 01/2020
1	Lung Neoplasms (Lung Cancer) 11/2019
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2019
1	Exanthema (Rash) 01/2018
1	Ovarian Epithelial Carcinoma 01/2017

Drug/Important Bio-Agent (IBA)

22	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2022 - 05/2011
9	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 05/2013
8	VemurafenibIBA 01/2018 - 02/2012
7	Chloroquine (Aralen)FDA LinkGeneric 05/2021 - 02/2007
7	Pharmaceutical PreparationsIBA 01/2020 - 02/2011
6	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2015
5	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2016
5	Lys01IBA 11/2019 - 05/2012
4	dabrafenibIBA 01/2022 - 09/2013
4	trametinibIBA 01/2022 - 09/2013
4	Proteins (Proteins, Gene)FDA Link 01/2016 - 09/2013
4	Temozolomide (Temodar)FDA LinkGeneric 08/2014 - 12/2009
4	Sorafenib (BAY 43-9006)FDA Link 12/2012 - 03/2008
3	IpilimumabIBA 01/2022 - 01/2019
3	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 05/2012
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2017 - 08/2014
3	Small Interfering RNA (siRNA)IBA 01/2017 - 02/2007
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2019
2	SteroidsIBA 01/2022 - 01/2021
2	Mitogen-Activated Protein KinasesIBA 11/2021 - 04/2015
2	Gemcitabine FDA Link 01/2020 - 07/2019
2	Phosphotransferases (Kinase)IBA 01/2020 - 03/2008
2	130-nm albumin-bound paclitaxelIBA 01/2020 - 07/2019
2	Endoplasmic Reticulum Chaperone BiPIBA 01/2019 - 03/2014
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 06/2013
2	CateninsIBA 11/2017 - 12/2015
2	Drug CombinationsIBA 01/2017 - 01/2017
2	Estrogen ReceptorsIBA 01/2017 - 02/2007
2	RNA (Ribonucleic Acid)IBA 01/2017 - 01/2017
2	LigandsIBA 12/2016 - 01/2015
2	birinapantIBA 11/2015 - 04/2013
2	Bevacizumab (Avastin)FDA Link 08/2015 - 06/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2015 - 04/2015
1	GlucocorticoidsIBA 01/2022
1	regorafenibIBA 01/2022
1	Prednisone (Sone)FDA LinkGeneric 01/2022
1	entinostat (MS 275)IBA 01/2022
1	Biological ProductsIBA 10/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	N-acetyltalosaminuronic acid (NAT)IBA 08/2020
1	niraparibIBA 01/2020
1	AntigensIBA 01/2020
1	Apoptosis Regulatory ProteinsIBA 01/2020
1	palmitoyl-protein thioesteraseIBA 01/2020
1	Conditioned Culture MediaIBA 01/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020
1	talazoparibIBA 01/2020
1	SAR405IBA 01/2020
1	rucaparibIBA 01/2020
1	Poly Adenosine Diphosphate RiboseIBA 01/2020
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2020
1	olaparibIBA 01/2020
1	Retinaldehyde (Retinal)IBA 03/2019
1	Fc Receptors (Fc Receptor)IBA 01/2019
1	Everolimus FDA Link 01/2019
1	AntibodiesIBA 01/2019
1	Interleukin-15 (Interleukin 15)IBA 01/2019
1	MTOR InhibitorsIBA 01/2019
1	NucleosidesIBA 10/2018
1	alpha-2'-deoxythioguanosineIBA 10/2018
1	Telomerase (Telomerase Reverse Transcriptase)IBA 10/2018
1	PX-866IBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Cell-Free Nucleic AcidsIBA 01/2018
1	Mechanistic Target of Rapamycin Complex 1IBA 11/2017
1	palbociclibIBA 01/2017
1	Sunitinib (Sutent)FDA Link 01/2017

Therapy/Procedure

46	Therapeutics 01/2022 - 02/2007
9	Immunotherapy 01/2022 - 01/2018
9	Drug Therapy (Chemotherapy) 01/2020 - 02/2007
2	Radiotherapy 01/2021 - 08/2014
1	Mohs Surgery (Mohs' Micrographic Surgery) 10/2021
1	Aftercare (After-Treatment) 01/2017